October 11, 2024
Several new studies on gynecologic conditions have started in recent months. Perhaps one of your patients would be interested? Human papillomavirus (HPV) 16–positive, PD-L1–positive, persistent-recurrent or […]
October 11, 2024
The US Food and Drug Administration (FDA) has approved inavolisib (Itovebi, Genentech) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor–positive (HR+), human epidermal […]
October 10, 2024
TOPLINE: Cancer survivors who had overweight or obesity at the time of their initial cancer diagnosis have a higher risk for a second primary cancer, particularly […]
October 10, 2024
SAN DIEGO — CAR T-cell therapies offer the tantalizing prospect of dramatically altering the outcome of lung cancers, but there are many hurdles to treating patients […]
October 10, 2024
(Reuters) – Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate […]
October 9, 2024
TOPLINE: A recent analysis, evaluating an intervention in which patients with non–small cell lung cancer (NSCLC) used a wearable device to help monitor exercise post-surgery, found […]
October 9, 2024
RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a […]
October 9, 2024
Thanks to the continuously improving treatment options for cancer, the number of cancer survivors is increasing, and a large proportion of survivors is confronted with the […]
October 8, 2024
Breast cancer incidence has been on the rise, particularly among White women under age 50, but breast cancer deaths — for some, but not all, populations […]